Opportunity Information: Apply for PAR 24 129
The NIH funding opportunity PAR-24-129, titled "Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed)," is a discretionary health-related cooperative agreement designed to continue supporting a small set of already-established macaque breeding colonies that serve HIV/AIDS research needs. The core goal is continuity: this NOFO specifically targets colonies that were previously funded under PAR-21-089 and PAR-18-669, recognizing that maintaining high-quality, research-ready nonhuman primate resources is a long-term infrastructure commitment rather than a short, one-off project. By keeping these colonies stable and productive, the program helps ensure a reliable supply of animals that are appropriate for studies of HIV and related viruses, including simian immunodeficiency virus (SIV), which is widely used in nonhuman primate models of AIDS.
A central focus of the program is the maintenance of "specific pathogen-free" (SPF) macaques with documented pedigrees. In this context, SPF means the animals are free of particular viruses that could otherwise complicate research outcomes or introduce safety concerns for animal care and research personnel. Those background infections can change immune function, alter disease progression, or interfere with interpreting experimental readouts, which is especially problematic in HIV/AIDS research where immune responses and virologic measures are central endpoints. The NOFO emphasizes that breeding colonies are essential infrastructure because they are the mechanism by which an ongoing, predictable pipeline of these appropriately screened animals is produced and sustained over time.
Beyond pathogen status, the NOFO highlights genetic characterization, specifically major histocompatibility complex (MHC) class I typing. This matters because MHC class I genotypes can strongly influence how macaques respond immunologically to SIV infection and SIV-based challenge studies, which in turn affects key research outcomes relevant to HIV vaccine development, cure strategies, immunotherapies, and pathogenesis. By maintaining colonies where animals are both SPF and genetically characterized for MHC class I, the program supports better-controlled experiments and improves the ability of researchers to compare results across studies, cohorts, and time. In practical terms, having animals with known MHC class I backgrounds can reduce variability, support better study design (for example, balancing genotype distributions across study arms), and help interpret immune correlates of protection or disease progression.
This is a cooperative agreement (U42), meaning NIH anticipates substantial programmatic involvement compared with a standard research project grant. The opportunity is also explicitly "Clinical Trial Not Allowed," reflecting that the award supports a resource and infrastructure function (the establishment and maintenance of colonies and associated characterization) rather than clinical intervention studies. The NOFO is labeled a limited competition, which aligns with its stated purpose of continuing support for specific colonies previously funded under the earlier announcements rather than opening a broad, fully open competition to all potential applicants.
Eligibility is restricted. The source information indicates eligible applicants include public and state-controlled institutions of higher education, and the NOFO text makes clear that foreign organizations are not eligible to apply. It also excludes non-domestic components of U.S. organizations and does not allow foreign components as defined by the NIH Grants Policy Statement. In other words, this program is intended to be administered and carried out entirely within eligible U.S.-based institutional structures, and applicants should pay close attention to the specific eligibility language in the NOFO to confirm they fit the limited, continuation-oriented scope.
Administrative details provided include that the sponsoring agency is the National Institutes of Health, the opportunity falls under CFDA numbers 93.310 and 93.351, and the original closing date listed is 2027-01-07. The NOFO was created on 2024-01-22. An award ceiling and expected number of awards are not specified in the provided source fields, which often means applicants must consult the full NOFO text for budget parameters, anticipated award counts, and any institute-specific funding expectations.
Overall, this funding opportunity is best understood as NIH support for specialized national research infrastructure: maintaining well-controlled, pedigree SPF macaque colonies with relevant genetic typing so HIV/AIDS investigators can access animals that are both safer to work with and scientifically appropriate for immune-focused SIV/HIV modeling. The emphasis on continuity from prior awards, strict eligibility limits, and the cooperative agreement mechanism all reinforce that NIH is sustaining a critical, curated resource rather than funding unrelated new colony efforts or broad exploratory research projects.Apply for PAR 24 129
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310, 93.351.
- This funding opportunity was created on 2024-01-22.
- Applicants must submit their applications by 2027-01-07.
- Eligible applicants include: Public and State controlled institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH PAR-24-129 (U42) - Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research
What is PAR-24-129?
PAR-24-129 is an NIH funding opportunity titled "Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed)." It supports the continued operation of established macaque breeding colonies that provide research-ready animals for HIV/AIDS-related studies.
What is the main purpose of this funding opportunity?
The purpose is continuity. The program is designed to keep a small set of already-established macaque colonies stable, productive, and available to meet ongoing HIV/AIDS research needs, rather than funding short-term projects or new colony start-ups.
Is this opportunity open to any macaque breeding colony?
No. It is a limited competition aimed at continuing support for specific colonies that were previously funded under earlier NIH announcements (PAR-21-089 and PAR-18-669). The intent is to sustain existing, previously supported infrastructure.
Which prior funding opportunities are connected to PAR-24-129?
This NOFO is specifically tied to colonies previously funded under PAR-21-089 and PAR-18-669, reflecting NIH's focus on maintaining established resources over time.
What type of NIH award mechanism is used?
The mechanism is a cooperative agreement (U42). This typically indicates NIH expects substantial programmatic involvement compared with a standard research project grant.
What does "cooperative agreement" (U42) imply in practice?
Based on the description provided, NIH anticipates being more involved programmatically than it would be under a typical research grant, because the award supports specialized infrastructure and ongoing colony operations rather than a discrete research experiment.
Are clinical trials allowed under this opportunity?
No. The opportunity is explicitly labeled "Clinical Trial Not Allowed," reflecting that the award supports resource and infrastructure activities (colony maintenance and characterization), not clinical intervention studies.
What research area does this opportunity support?
It supports HIV/AIDS research by maintaining macaque colonies that can supply animals appropriate for studies involving HIV and related viruses, including simian immunodeficiency virus (SIV), which is commonly used in nonhuman primate models of AIDS.
What is meant by "specific pathogen-free" (SPF) macaques in this context?
In this program, SPF macaques are animals that are free of particular viruses that could complicate scientific results or introduce safety concerns. The SPF status helps reduce confounding infections that could alter immune function or disease progression.
Why is SPF status especially important for HIV/AIDS and SIV studies?
HIV/AIDS and SIV research often relies on immune responses and virologic measurements as central outcomes. Background infections can change immune behavior, affect disease course, and make it harder to interpret experimental readouts or compare results across studies.
Does the opportunity emphasize pedigree documentation?
Yes. The NOFO highlights SPF macaques with documented pedigrees, which supports colony management and helps ensure research suitability and consistency over time.
What genetic characterization is highlighted in the NOFO?
The opportunity emphasizes major histocompatibility complex (MHC) class I typing as a key genetic characterization activity for animals in supported colonies.
Why is MHC class I typing important for macaque-based HIV/SIV research?
MHC class I genotypes can strongly influence immune responses to SIV infection and SIV-based challenge studies. Knowing MHC class I backgrounds can improve study control, reduce variability, and help interpret immune correlates related to protection or disease progression.
How can known MHC class I backgrounds help study design?
With MHC class I typing information, researchers can better balance genotype distributions across study arms, compare cohorts more meaningfully across time, and interpret differences in immune outcomes with more confidence.
Is this funding intended for creating brand-new macaque colonies?
No. The description frames the award as continued support for already-established colonies previously funded under specific prior announcements, reinforcing an infrastructure continuity goal rather than a start-up effort.
Who is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
What applicant organizations are eligible based on the information provided?
Eligible applicants include public and state-controlled institutions of higher education. Eligibility is restricted and continuation-oriented, so applicants should align with the limited competition scope described.
Are foreign organizations eligible to apply?
No. Foreign organizations are not eligible to apply under this opportunity.
Are foreign components or non-domestic components allowed?
No. The information provided states that non-domestic components of U.S. organizations are excluded and foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
Does the program require work to be administered within the United States?
Yes. As described, the program is intended to be administered and carried out entirely within eligible U.S.-based institutional structures, without foreign or non-domestic components.
What are the CFDA numbers associated with this opportunity?
The opportunity is associated with CFDA numbers 93.310 and 93.351.
When was the NOFO created?
The NOFO was created on 2024-01-22.
What is the closing date listed for this opportunity?
The original closing date listed is 2027-01-07.
Is the award ceiling provided in the information above?
No. An award ceiling is not specified in the provided source fields.
Is the expected number of awards provided?
No. The expected number of awards is not specified in the provided source fields.
What should applicants do if they need budget limits or expected award counts?
Based on the information provided, those details are not included in the source fields, which typically means applicants would need to consult the full NOFO text for budget parameters, anticipated award counts, and any institute-specific expectations.
What is the overall role of this program in the research ecosystem?
It is best understood as NIH support for specialized national research infrastructure: maintaining well-controlled, pedigree SPF macaque colonies with relevant genetic typing so HIV/AIDS investigators can access animals that are safer to work with and scientifically appropriate for immune-focused SIV/HIV modeling.
Why does the NOFO frame macaque colonies as long-term infrastructure?
The description emphasizes that maintaining high-quality, research-ready nonhuman primate resources requires sustained effort over time, because stable breeding, screening, and characterization are ongoing commitments rather than one-time tasks.
Browse more opportunities from the same category: Health
Next opportunity: Confronting Hazards, Impacts and Risks for a Resilient Planet
Previous opportunity: Early-stage Biomedical Data Repositories and Knowledgebases (R24 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 24 129
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 24 129) also looked into and applied for these:
| Funding Opportunity |
|---|
| Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed) Apply for PAR 24 112 Funding Number: PAR 24 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed) Apply for PAR 24 111 Funding Number: PAR 24 111 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Evaluation and Coordinating Center for the AHRQ/PCORI Learning Health System Embedded Scientist Training and Research Centers (U18) Apply for RFA HS 24 002 Funding Number: RFA HS 24 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $1,000,000 |
| Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed) Apply for RFA AI 24 003 Funding Number: RFA AI 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| USAID/Kenya and East Africa Global Health Security (GHS) Activity Apply for 72061524RFI00002 Funding Number: 72061524RFI00002 Agency: Kenya USAID-Nairobi Category: Health Funding Amount: Case Dependent |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) Apply for PAR 24 099 Funding Number: PAR 24 099 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) Apply for PAR 24 100 Funding Number: PAR 24 100 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Localization in Health Apply for 620 24 0002 Funding Number: 620 24 0002 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: Case Dependent |
| NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) Apply for PAR 24 124 Funding Number: PAR 24 124 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) Apply for PAR 24 116 Funding Number: PAR 24 116 Agency: National Institutes of Health Category: Health Funding Amount: $1,050,000 |
| NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) Apply for PAR 24 115 Funding Number: PAR 24 115 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 24 123 Funding Number: PAR 24 123 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID Strengthening Local Health Security Apply for 72044024RFA00001 Funding Number: 72044024RFA00001 Agency: USAID-VIETNAM Category: Health Funding Amount: $21,500,000 |
| Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) Apply for PAR 24 147 Funding Number: PAR 24 147 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed) Apply for PAR 24 148 Funding Number: PAR 24 148 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R01 Clinical Trial Not Allowed) Apply for RFA AG 25 016 Funding Number: RFA AG 25 016 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| AHRQ Small Health Services Research Grant Program (R03) Apply for PA 24 155 Funding Number: PA 24 155 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $100,000 |
| AHRQ Health Services Research Projects (R01) Apply for PA 24 154 Funding Number: PA 24 154 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required) Apply for PAR 24 125 Funding Number: PAR 24 125 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Health Services Research Demonstration and Dissemination Grants (R18) Apply for PA 24 156 Funding Number: PA 24 156 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 24 129", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.